ConductScience.org, home

Paper32423643

Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.

Pertejo-Fernandez A and 7 others. Lung Cancer, 2020. Cited by 39 papers, by iCite.

Cite this record

ConductScience Library. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Papers, record 32423643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32423643

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
PubMed
Journal
Lung Cancer
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
39
iCite
Relative citation ratio, by iCite
1.62
iCite
Revised in PubMed
2021-06-21
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pertejo-Fernandez AAna
2Ricciuti BBiagio
3Hammond SPSarah P
4Marty FMFrancisco M
5Recondo GGonzalo
6Rangachari DDeepa
7Costa DBDaniel B
8Awad MMMark M

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Hepatitis BMajor topic
Hepatitis CMajor topic
Lung NeoplasmsMajor topic
Humans
Immune Checkpoint Inhibitors
Retrospective Studies

Source PubMed

Download CSV of topics

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.

PMIDTitleJournalYearIn PapersSource
42281419KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA).Clin Mol Hepatol2026https://conductscience.org/library/papers/42281419PubMed
42125666Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk.Front Immunol2026https://conductscience.org/library/papers/42125666PubMed
41606625Cross-domain neural collaborative filtering for personalized herbal prescription recommendation.Chin Med2026https://conductscience.org/library/papers/41606625PubMed
40897718Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.NPJ Biofilms Microbiomes2025https://conductscience.org/library/papers/40897718PubMed
40841937Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B.BMC Cancer2025https://conductscience.org/library/papers/40841937PubMed
38721408Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.J Immunother Precis Oncol2024https://conductscience.org/library/papers/38721408PubMed
38161553The Missed Opportunity: HIV, Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) Positive Patients in Neoadjuvant and Perioperative Immunotherapy Clinical Trials for Lung Cancer.Cureus2023https://conductscience.org/library/papers/38161553PubMed
37736699Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Infect Dis Poverty2023https://conductscience.org/library/papers/37736699PubMed
36936956Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk.Front Immunol2023https://conductscience.org/library/papers/36936956PubMed
36871274Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).Cancer Immunol Immunother2023https://conductscience.org/library/papers/36871274PubMed
36762057Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).Transl Lung Cancer Res2023https://conductscience.org/library/papers/36762057PubMed
36647390Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis.J Oncol2023https://conductscience.org/library/papers/36647390PubMed
36484006Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.J Cancer2022https://conductscience.org/library/papers/36484006PubMed
36425873An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).Ther Adv Med Oncol2022https://conductscience.org/library/papers/36425873PubMed
35938033Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.Front Genet2022https://conductscience.org/library/papers/35938033PubMed
35767193Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.J Cancer Res Clin Oncol2023https://conductscience.org/library/papers/35767193PubMed
35663533Reactivation of Hepatitis B Virus Among Patients With Cancer Receiving Immunotherapy.J Immunother Precis Oncol2021https://conductscience.org/library/papers/35663533PubMed
35601125Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.JGH Open2022https://conductscience.org/library/papers/35601125PubMed
35256688Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment.Sci Rep2022https://conductscience.org/library/papers/35256688PubMed
34607905Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.Thorax2022https://conductscience.org/library/papers/34607905PubMed

See all 30 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32423643

GET https://conductscience.org/api/papers/v1/32423643/cited_by?page=2